title: [Waived EEG diagnosis before administration and during drug therapy with methylphenidate: dangerous or justifiable?].
abstract: OBJECTIVE
  The issue of whether or not to perform an EEG before or during therapy with psychostimulants currently is a topic of controversial discussion. Only a few studies have described the types of EEG alterations that occur in patients without epilepsy who are being treated with psychostimulants. The aim of our study was to assess the types of change in the EEG that occur before and during this treatment so as to be able to formulate recommendations for EEGs in children with ADHD.
  
  
  METHODS
  The EEGs of 124 children and adolescents with ADHD before and during treatment with methylphenidate were analyzed retrospectively.
  
  
  RESULTS
  In summary the rate of hypersynchronous activity (HSA) during therapy with methylphenidate does not increase. Patients on antiepileptic medication did not show any increased rates of seizures or HSA.
  
  
  CONCLUSIONS
  Whether or not methylphenidate medication influences the occurrence of epileptic seizures remains unsettled. Given the data from this study, we would conclude that an EEG during therapy with methylphenidate is not necessary. Before commencing a planned methylphenidate therapy, however, an EEG should be performed.
authors.affiliation: Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters, Universität Köln.
authors.forename: J K
authors.initials: JK
authors.lastname: Schmidt
authors.forename: J
authors.initials: J
authors.lastname: Plück
authors.forename: A
authors.initials: A
authors.lastname: von Gontard
mesh_terms: D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects* / Q000627:therapeutic use; D002540:Cerebral Cortex / Q000187:drug effects; D002648:Child; D004569:Electroencephalography / Q000187:drug effects*; D004827:Epilepsy / Q000139:chemically induced; D006801:Humans; D008774:Methylphenidate / Q000009:adverse effects* / Q000627:therapeutic use; D012306:Risk
chemical_list: D000697:Central Nervous System Stimulants; D008774:Methylphenidate